Across TCGA pan-cancer cohorts, CFHR1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CFHR1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CFHR1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFHR1 expression acts as an unfavorable survival marker.
KIRC and UCEC are the cancer types where CFHR1 Mutation most reproducibly stratifies survival.